Inhibitory effects of lapachol derivatives on Epstein-Barr virus activation

被引：78
作者：
Sacau, EP
Estévez-Braun, A
Ravelo, AG
Ferro, EA
Tokuda, H
Mukainaka, T
Nishino, H
机构：
[1] Univ La Laguna, Inst Univ Bioorgan Antonio Gonzalez, E-38206 Tenerife, Spain
[2] Kyoto Prefectural Univ Med, Dept Biochem, Kyoto 602, Japan
[3] Univ Asuncion, Dept Fitoquim, Asuncion, Paraguay
来源：
BIOORGANIC & MEDICINAL CHEMISTRY | 2003年 / 11卷 / 04期
关键词：
D O I：
10.1016/S0968-0896(02)00542-4
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Sixteen derivatives (2-17) synthesized from the naphthoquinone lapachol (1), were tested for their inhibitory effects on Epstein-Barr virus early antigen (EBV-EA) activation induced by 12-O-tetradecanoylphorbol-13-acetate (TPA), as a test for potential cancer chemopreventive agents. They exhibited a variety of inhibitory activities from very high to moderate, which allow us to suggest structure-activity relationships. Ten of these derivatives are reported for the first time, their structures being thoroughly determined by spectroscopic methods. (C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码：483 / 488
页数：6
相关论文
共 50 条
[31]   Correlation between reduction potentials and inhibitory effects on Epstein-Barr virus activation of poly-substituted anthraquinones [J].
Koyama, J ;
Morita, I ;
Kobayashi, N ;
Osakai, T ;
Nishino, H ;
Tokuda, H .
CANCER LETTERS, 2005, 225 (02) :193-198
[32]   3-epicabraleabydroxylactone and other triterpenoids from camellia oil and their inhibitory effects on Epstein-Barr virus activation [J].
Akihisa, T ;
Tokuda, H ;
Ukiya, M ;
Suzuki, T ;
Enjo, F ;
Koike, K ;
Nikaido, T ;
Nishino, H .
CHEMICAL & PHARMACEUTICAL BULLETIN, 2004, 52 (01) :153-156
[33]   ACTIVATION OF EPSTEIN-BARR VIRUS IN HYBRID-CELLS [J].
TSANG, KY ;
HANN, WD .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1977, 58 (05) :1295-1301
[34]   Correlation between reduction potentials and inhibitions of Epstein-Barr virus activation by anthraquinone derivatives [J].
Koyama, Junko ;
Nisino, Yu ;
Morita, Izumi ;
Kobayashi, Norihiro ;
Osakai, Toshiyuki ;
Tokuda, Harukuni .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (14) :4106-4109
[35]   ACTIVATION OF LYMPHOCYTES FROM EPSTEIN-BARR VIRUS-SERONEGATIVE DONORS BY AUTOLOGOUS EPSTEIN-BARR VIRUS-TRANSFORMED CELLS [J].
CHANG, RS ;
CHANG, YY .
JOURNAL OF INFECTIOUS DISEASES, 1980, 142 (02) :156-162
[36]   Inhibitory effects of some derivatives of glycyrrhizic acid against Epstein-Barr virus infection: Structure-activity relationships [J].
Lin, Jung-Chung ;
Cherng, Jaw-Ming ;
Hung, Man-Shan ;
Baltina, Lidia A. ;
Baltina, Lia ;
Kondratenko, Rimma .
ANTIVIRAL RESEARCH, 2008, 79 (01) :6-11
[37]   Epstein-Barr virus vectors for the treatment of Epstein-Barr virus-associated cancers [J].
Paillard, F .
HUMAN GENE THERAPY, 1998, 9 (08) :1119-1120
[38]   Serum Epstein-Barr virus DNA load in primary Epstein-Barr virus infection [J].
Bauer, CC ;
Aberle, SW ;
Popow-Kraupp, T ;
Kapitan, M ;
Hofmann, H ;
Puchhammer-Stöckl, E .
JOURNAL OF MEDICAL VIROLOGY, 2005, 75 (01) :54-58
[39]   Inhibitory effects of fatty acid monoesters of 2-O-β-D-glucosylglycerol on Epstein-Barr virus activation [J].
Colombo, D ;
Scala, A ;
Taino, IM ;
Toma, L ;
Ronchetti, F ;
Tokuda, H ;
Nishino, H ;
Nagatsu, A ;
Sakakibara, J .
CANCER LETTERS, 1998, 123 (01) :83-86
[40]   Inhibitory effects of monoacylated 2-O-β-galactosylglycerols on Epstein-Barr virus activation:: the significant role of the hexanoyl chain [J].
Colombo, D ;
Compostella, F ;
Ronchettia, F ;
Scala, A ;
Toma, L ;
Mukainaka, T ;
Nagatsu, A ;
Konoshima, T ;
Tokuda, H ;
Nishino, H .
CANCER LETTERS, 1999, 143 (01) :1-4
12345